BACKGROUND: Understanding the impact of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) coinfection has been limited by heterogeneity of HIV disease. We evaluated HBV coinfection and HIV-related disease progression in a cohort of HIV seroconverters. METHODS: Participants with HIV diagnosis seroconversion window of ≤ 3 years and serologically confirmed HBV infection (HB) status were classified at baseline into 4 HB groups. The risk of clinical AIDS/death in HIV seroconverters was calculated by HB status. RESULTS: Of 2352 HIV seroconverters, 474 (20%) had resolved HB, 82 (3%) had isolated total antibody to hepatitis B core antigen (HBcAb), and 64 (3%) had chronic HB. Unadjusted rates (95% confidence intervals [CIs]) of clinical AIDS/death for the HB-negative, resolved HB, isolated HBcAb, and chronic HB groups were 2.43 (2.15-2.71); 3.27 (2.71-3.84); 3.75 (2.25-5.25); and 5.41 (3.41-7.42), respectively. The multivariable risk of clinical AIDS/death was significantly higher in the chronic HB group compared to the HB-negative group (hazard ratio [HR], 1.80; 95% CI, 1.20-2.69); while the HRs were increased but nonsignificant for those with resolved HB (HR, 1.17; 95% CI, .94-1.46) and isolated HBcAb (HR, 1.14; 95% CI, .75-1.75). CONCLUSIONS: HBV coinfection has a significant impact on HIV outcomes. The hazard for an AIDS or death event is almost double for those with chronic HB compared, with HIV-monoinfected persons.
BACKGROUND: Understanding the impact of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) coinfection has been limited by heterogeneity of HIV disease. We evaluated HBV coinfection and HIV-related disease progression in a cohort of HIV seroconverters. METHODS:Participants with HIV diagnosis seroconversion window of ≤ 3 years and serologically confirmed HBV infection (HB) status were classified at baseline into 4 HB groups. The risk of clinical AIDS/death in HIV seroconverters was calculated by HB status. RESULTS: Of 2352 HIV seroconverters, 474 (20%) had resolved HB, 82 (3%) had isolated total antibody to hepatitis B core antigen (HBcAb), and 64 (3%) had chronic HB. Unadjusted rates (95% confidence intervals [CIs]) of clinical AIDS/death for the HB-negative, resolved HB, isolated HBcAb, and chronic HB groups were 2.43 (2.15-2.71); 3.27 (2.71-3.84); 3.75 (2.25-5.25); and 5.41 (3.41-7.42), respectively. The multivariable risk of clinical AIDS/death was significantly higher in the chronic HB group compared to the HB-negative group (hazard ratio [HR], 1.80; 95% CI, 1.20-2.69); while the HRs were increased but nonsignificant for those with resolved HB (HR, 1.17; 95% CI, .94-1.46) and isolated HBcAb (HR, 1.14; 95% CI, .75-1.75). CONCLUSIONS:HBV coinfection has a significant impact on HIV outcomes. The hazard for an AIDS or death event is almost double for those with chronic HB compared, with HIV-monoinfected persons.
Authors: Sang Hoon Ahn; Do Young Kim; Hye Young Chang; Sun Pyo Hong; Jeon-Soo Shin; Yu Seun Kim; Hyejin Kim; Ja Kyung Kim; Yong Han Paik; Kwan Sik Lee; Chae Yoon Chon; Young Myoung Moon; Kwang-Hyub Han Journal: J Med Virol Date: 2006-12 Impact factor: 2.327
Authors: Jeroen N Stoop; Renate G van der Molen; Carla C Baan; Luc J W van der Laan; Ernst J Kuipers; Johannes G Kusters; Harry L A Janssen Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: R Monica Lascar; A Ross Lopes; Richard J Gilson; Claire Dunn; Ruth Johnstone; Andrew Copas; Stephanie Reignat; George Webster; Antonio Bertoletti; Mala K Maini Journal: J Infect Dis Date: 2005-02-28 Impact factor: 5.226
Authors: Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren Journal: J Infect Dis Date: 2005-08-11 Impact factor: 5.226
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: T R Dinesha; J Boobalan; S Sivamalar; D Subashini; S S Solomon; K G Murugavel; P Balakrishnan; D M Smith; S Saravanan Journal: J Viral Hepat Date: 2018-02-19 Impact factor: 3.728
Authors: Carmen Pittman; Sabrina Plitt; Ted Birse; Karen Doucette; Barbara Romanowski; Rya Cooper; Stan Houston; Stephen Shafran; Ameeta E Singh Journal: Can J Infect Dis Med Microbiol Date: 2014 Impact factor: 2.471